Efficacy and Toxicity of Panitumumab After Progression on Cetuximab and Predictive Value of MiR-31-5p in Metastatic Wild-type KRAS Colorectal Cancer Patients

Varování

Publikace nespadá pod Ekonomicko-správní fakultu, ale pod Středoevropský technologický institut. Oficiální stránka publikace je na webu muni.cz.
Název česky Efektivita a toxicita panitumumabu po progresi na cetuximabu a prediktivní význam MiR-31-5p u pacientů s metastatickým divokým KRAS colorektálním karcinomem
Autoři

KISS Igor MLČOCHOVÁ Jitka BORTLÍČEK Zbyněk POPRACH Alexandr DRÁBEK Jiří VYCHYTILOVÁ Petra SVOBODA Marek BÜCHLER Tomáš BATKO Stanislav RYŠKA Aleš HAJDÚCH Marian SLABÝ Ondřej

Rok publikování 2016
Druh Článek v odborném periodiku
Časopis / Zdroj Anticancer Research
Fakulta / Pracoviště MU

Středoevropský technologický institut

Citace
www http://ar.iiarjournals.org/content/36/9/4955.abstract
Doi http://dx.doi.org/10.21873/anticanres.11063
Obor Onkologie a hematologie
Klíčová slova KRAS; Metastatic colorectal cancer; cetuximab; miR-31-5p; microRNA; panitumumab
Popis Background: In metastatic colorectal cancer (mCRC), panitumumab is generally considered to be ineffective after the progression on cetuximab therapy. However, few studies have demonstrated that a small subset of mCRC patients may benefit from panitumumab in this setting. Patients and Methods: In our study, wild-type KRAS mCRC patients, enrolled into the nationwide Czech registry CORECT between January 2007 and December 2012, were screened for panitumumab therapy after progression on cetuximab. Results: We identified 26 mCRC in the registry with well documented progression on cetuximab in combination with irinotecan-based chemotherapy (FOLFIRI or irinotecan alone) who received panitumumab monotherapy. Partial response (PR) was achieved in 3 (11.5%) patients and stable disease (SD) in 7 (26.9%) patients after 8 weeks of therapy. Thirteen (50.0%) patients had evidence of progressive disease (PD) and in 3 (11.5%) cases response was not available. Furthermore, we confirmed that higher expression levels of newly described biomarker, miR-31-5p, in tumor are significantly associated with shorter progression-free survival (PFS) in patients treated with cetuximab (p=0.038); however, we did not observe association between miR-31-5p and response to panitumumab in mCRC patients after progression on cetuximab. Conclusion: It remains possible that a subset of mCRC patients may benefit from panitumumab after progression on cetuximab.
Související projekty:

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.